drugset
drugset / Trial / NCT05208840

A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis

NCT05208840 ↗

Phase 4 Withdrawn Hoffmann-La Roche
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the evolution of leptomeningeal lesions via leptomeningeal contrast enhancement (LMCE) presence/disappearance after treatment administration in patients with active progressive multiple sclerosis (MS). In addition, this study will investigate if the presence of leptomeningeal inflammation is associated with alterations of B cell repertoire and whether therapy with ocrelizumab will lead to change of B cell repertoire in LMCE-positive patients.

Timeline

Start
2023-09-15
Primary completion
2025-01-31
Completion
2026-01-31

Outcome

Outcome not reported

Stopped: “Due to deterioration of the geopolitical situation and escalation of conflict between Russia and Ukraine ML42302 study was put on hold.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Ocrelizumab Monoclonal antibody 600 mg Intravenous

Indications

multiple sclerosis